Compare Amphastar Pharmaceuticals Inc (AMPH) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Redwire Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Redwire Corporation trades at $10.08 (market cap $2.43B). The key difference: Redwire Corporation is far larger — about 2.9× Amphastar Pharmaceuticals Inc's market cap, and Redwire Corporation is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | RDW | |
|---|---|---|
Market Cap | $826.08M | $2.43B |
Sector | Health | Technology |
52-Week High | $30.81 | $25.90 |
52-Week Low | $16.87 | $5.06 |
Enterprise Value | $1.22B | $2.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
RDW trades at $10.18, down 2.77% today amid bearish technical signals despite bullish analyst sentiment. The stock shows weak fundamentals with a -80.9% net income margin and three consecutive quarterly EPS misses. Recent news highlights volatility driven by SpaceX's market impact and RDW's capital raising activities, though new defense contracts provide some optimism.
The outlook remains high-risk due to persistent losses and cash burn, but analyst consensus suggests 87% upside to the $19 price target. Key risks include dilution from fundraising and intense space sector competition, requiring careful monitoring of profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
